CXCL12 and myeloid sarcoma: CXCL12/CXCR4 (CXCL12 reduced in MS patient CSF cells and EAE spinal cord. Administration of antagonist AMD3100 to a weak EAE rats led to earlier disease onset. In mouse EAE, AMD3100 exacerbates disease by promoting leukocyte infiltration into the CNS parenchyma.)